JSKN016

Phase 2Small molecule

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

JSKN016 is one of 99 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerNot yet recruiting

Advanced Malignant Solid TumorsRecruiting

Combination TherapyNot yet recruiting

Phase II Clinical StudyNot yet recruiting

Breast CancerPhase 2

Not yet recruiting

Advanced Malignant Solid TumorsPhase 1

Recruiting

Combination TherapyPhase 1

Not yet recruiting

Phase II Clinical StudyPhase 2

Not yet recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

JSKN016

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2

2 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Preclinical

—7

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 8

Tianeptine

Pfizer

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Bisphosphonate

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Advanced Malignant Solid Tumors

NCT06592417

Q4 2027

Phase 2Not yet recruiting

Phase II Clinical Study

NCT06775483

Phase 1/2Recruiting

Breast Cancer

NCT06942234

Q2 2028

Phase 1/2Not yet recruiting

Breast Cancer

NCT07336771

Q4 2028

Phase 1Not yet recruiting

Combination Therapy

NCT06868732

Clinical

Trials by Indication[1]

Breast Cancer2 trials

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Not yet recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1/2·NCT07336771·60 enrolled

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1/2·NCT06942234·180 enrolled

Combination Therapy1 trial

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Not yet recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1·NCT06868732·288 enrolled

Phase II Clinical Study1 trial

Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study

Not yet recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT06775483·220 enrolled

Advanced Malignant Solid Tumors1 trial

To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

Recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1·NCT06592417·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for JSKN016. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JSKN016 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JSKN016. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Alphamab Biopharmaceuticals Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJiangsu Alphamab Biopharmaceuticals Co., Ltd

JSKN016

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Breast Cancer2 trials

Combination Therapy1 trial

Phase II Clinical Study1 trial

Advanced Malignant Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News